Trials / Completed
CompletedNCT00946751
To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions
Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Sandoz · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levetiracetam Tablets, 750 mg (Sandoz Inc.) | |
| DRUG | Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc) |
Timeline
- Start date
- 2004-03-01
- Primary completion
- 2004-03-01
- Completion
- 2004-03-01
- First posted
- 2009-07-27
- Last updated
- 2017-03-28
Source: ClinicalTrials.gov record NCT00946751. Inclusion in this directory is not an endorsement.